tetano
Editor, Senior Moderator
Cureus
. 2022 Apr 13;14(4):e24126.
doi: 10.7759/cureus.24126. eCollection 2022 Apr.
Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine
Amar D Desai[SUP] 1 [/SUP], Radhika Shah[SUP] 2 [/SUP], Attiya Haroon[SUP] 2 [/SUP], Cindy Wassef[SUP] 2 [/SUP]
Affiliations
Abstract
As the onset of novel variants of the severe acute respiratory syndrome coronavirus 2 virus pushes policy-makers to push widespread vaccination efforts, it is likely that an increased number of severe cutaneous adverse reactions (SCARs) will present. Therefore, it is important to understand the presentation of possible SCARs. However, data are limited regarding which SCARs are most likely to be found following vaccination, and specific presentations in certain demographic groups, such as postmenopausal women, remain widely unknown. Here, we present the case of a 73-year-old female with no medical history or allergies presenting with a unique reaction of systemic bullous pemphigoid following the Moderna mRNA-1273 vaccine. To our knowledge at the time of this writing, based on a thorough review of the literature using PubMed, no such cases exist following the Moderna vaccine in the United States in elderly, postmenopausal women. We present a brief discussion on the presentation and management to hopefully alleviate future morbidity from similar reactions with increased distribution of the vaccine.
Keywords: bullous pemphigoid; covid-19 vaccine; moderna mrna 1273; moderna vaccine; sars-cov-2 vaccine; scars; vaccination reaction.
. 2022 Apr 13;14(4):e24126.
doi: 10.7759/cureus.24126. eCollection 2022 Apr.
Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine
Amar D Desai[SUP] 1 [/SUP], Radhika Shah[SUP] 2 [/SUP], Attiya Haroon[SUP] 2 [/SUP], Cindy Wassef[SUP] 2 [/SUP]
Affiliations
- PMID: 35573488
- PMCID: PMC9106564
- DOI: 10.7759/cureus.24126
Abstract
As the onset of novel variants of the severe acute respiratory syndrome coronavirus 2 virus pushes policy-makers to push widespread vaccination efforts, it is likely that an increased number of severe cutaneous adverse reactions (SCARs) will present. Therefore, it is important to understand the presentation of possible SCARs. However, data are limited regarding which SCARs are most likely to be found following vaccination, and specific presentations in certain demographic groups, such as postmenopausal women, remain widely unknown. Here, we present the case of a 73-year-old female with no medical history or allergies presenting with a unique reaction of systemic bullous pemphigoid following the Moderna mRNA-1273 vaccine. To our knowledge at the time of this writing, based on a thorough review of the literature using PubMed, no such cases exist following the Moderna vaccine in the United States in elderly, postmenopausal women. We present a brief discussion on the presentation and management to hopefully alleviate future morbidity from similar reactions with increased distribution of the vaccine.
Keywords: bullous pemphigoid; covid-19 vaccine; moderna mrna 1273; moderna vaccine; sars-cov-2 vaccine; scars; vaccination reaction.